Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pacira Pharmaceuticals

25.45
-0.4500-1.74%
Pre-market: 25.31-0.1400-0.55%04:50 EDT
Volume:717.50K
Turnover:18.36M
Market Cap:1.18B
PE:-11.82
High:26.36
Open:26.01
Low:25.18
Close:25.90
Loading ...

Company Profile

Company Name:
Pacira Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
789
Office Location:
5401 West Kennedy Boulevard,Suite 890,Tampa,Florida,United States
Zip Code:
33609
Fax:
- -
Introduction:
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Directors

Name
Position
David Stack
Director,Chief Executive Officer and Chairman
Andreas Wicki
Director
Gary Pace
Director
John Longenecker
Director
Laura Brege
Director
Mark A. Kronenfeld
Director
Mark I. Froimson
Director
Paul Hastings
Director
Yvonne Greenstreet
Director

Shareholders

Name
Position
David Stack
Director,Chief Executive Officer and Chairman
Charles A. Reinhart, III
Chief Financial Officer
Robert Weiland
Senior Vice President, Alliance Management
Kristen Williams
Chief Administrative Officer and Secretary
Richard Scranton
Chief Scientific Officer